Orphan Drugs | Access and Reimbursement | US | 2016
This detailed, expanded analysis explores key access and reimbursement topics in the rare disease space in the United States, such as the approaches managed care organizations take to control both utilization and costs of orphan drugs. The study further explores U.S. payers’ perspectives on market access considerations for several rare diseases including cystic fibrosis, Duchenne muscular dystrophy, hemophilia A, and idiopathic pulmonary fibrosis.
Related Market Assessment Reports
Report
Diabetic Nephropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Nephropathy (US)
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs…
Report
Bipolar Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Bipolar Depression (US)
Among bipolar disorder (BPD) patients, depressive episodes are typically more common than manic or mixed episodes; symptoms of bipolar depression include fatigue, insomnia, suicidal ideation, and…
Report
Binge Eating Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Binge Eating Disorder (US)
Binge eating disorder (BED) is a prevalent condition in the United States; it affects millions of individuals across diverse demographics. BED is characterized by recurrent episodes of excessive…
Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete as a result of opioid medications. The treatment of OIC relies on various prescription…
